CFTR interacts with Hsp90 and regulates the phosphorylation of AKT and ERK1/2 in colorectal cancer cells

Kaisheng Liu¹,², Hongtao Jin¹, Yaomin Guo¹, Ying Liu¹, Yong Wan¹, Pan Zhao¹, Zhifan Zhou¹, Jianhong Wang¹, Maolin Wang³, Chang Zou¹, Weiqing Wu¹, Zhiqiang Cheng¹ and Yong Dai¹

¹ The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen, China
² Faculty of Medicine, School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China
³ School of Medicine, Health Science Centre, Shenzhen University, Shenzhen, China

Keywords
AKT; cystic fibrosis transmembrane conductance regulator; extracellular signal-regulated kinase 1/2; heat-shock protein 90; mitochondria

Correspondence
Y. Dai, Z. Cheng and W. Wu, The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen 518020 Guangdong, China.
Fax/Tel: +86 755 22942107
E-mails: daiyong22@aliyun.com (YD); chengzhiqiang2004@aliyun.com (ZC); wweiqing007@sina.com (WW)

(Received 10 January 2019, revised 21 March 2019, accepted 12 April 2019)
doi:10.1002/2211-5463.12641

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CF cells and tissues exhibit various mitochondrial abnormalities. However, the underlying molecular mechanisms remain elusive. Here, we examined the mechanisms through which CFTR regulates Bcl-2 family proteins, which in turn regulate permeabilization of the mitochondrial outer membrane. Notably, inhibition of CFTR activated Bax and Bad, but inhibited Bcl-2. Moreover, degradation of phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT increased significantly in CFTR-knockdown cells. Dysfunction of CFTR decreased heat-shock protein 90 (Hsp90) mRNA levels, and CFTR was found to interact with Hsp90. Inhibition of Hsp90 by SNX-2112 induced the degradation of phosphorylated AKT and ERK1/2 in Caco2 and HRT18 cells. These findings may help provide insights into the physiological role of CFTR in CF-related diseases.

Cystic fibrosis (CF) is an autosomal recessive genetic disease that is most common in Caucasians that is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene [1]. CFTR encodes a cAMP-regulated anion channel expressed at the apical membrane of epithelial cells in various organs [2]. The CFTR channel can transport chloride, bicarbonate, and glutathione [3,4]. CFTR interacts either directly or indirectly with some proteins by forming a macromolecular complex [5–8]. More than 2000 mutations have been identified in CF, and deletion of the phenylalanine at position 508 (ΔF508) is the most frequent mutation occurring in over 80% of patients with CF [9–12]. CFTR mutations affect the mucosal physiology of the respiratory, digestive, and reproductive tracts, leading to systemic diseases, including pancreatic insufficiency, focal biliary cirrhosis, infertility, intestinal obstruction, increased cancer risk, and chronic airway obstruction [13,14].

Abbreviations
CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ERK1/2, extracellular signal-regulated kinase 1/2; Hsp90, heat-shock protein 90; shRNA, short hairpin RNA; ΔF508, deletion of the phenylalanine at position 508.
Interestingly, mitochondrial abnormalities have been found in CF cells and tissues [15–17]. For example, calcium uptake and oxygen consumption are altered in the mitochondria of patients with CF [18]. Additionally, fragmentation of mitochondria and a decrease in the mitochondrial membrane potential were observed in CF cells compared with control cells [19]. Mitochondrial proteins have also been shown to exhibit differences in the two-dimensional electrophoretic patterns in CF [20]. Moreover, reactive oxygen species and autophagy may be related to mitochondrial dysfunction in patients with CF [21–23]. However, the underlying molecular mechanisms remain elusive.

Thus, in this study, we aimed to evaluate the possible roles of CFTR in mitochondrial abnormalities. Our results provided important insights into the roles of CFTR in mitochondrial dysfunction via a mechanism involving heat-shock protein 90 (Hsp90)-mediated extracellular signal-regulated kinase (ERK) 1/2 and AKT, suggesting the involvement of CFTR in CF-related diseases.

Materials and methods

Antibodies and reagents

Anti-C-terminal-CFTR (CFTR-C) antibodies were purchased from Alomone Labs (Jerusalem, Israel) and anti-CFTR antibodies were from Cell Signaling Technology (Danvers, MA, USA). Anti-β-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Bcl-2, anti-Bax, anti-Bad, anti-ERK1/2, anti-AKT, anti-phospho-ERK1/2, and anti-phospho-Akt antibodies were obtained from Cell Signaling Technology.

Cell culture and lentiviral transduction

The human colon cancer cell lines Caco2 and HRT18 (American Type Culture Collection, Manassas, VA, USA) were cultured in MEM or RPMI-1640, respectively, supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin in an incubator at 37 °C in an atmosphere containing 5% CO₂.

Lentiviral transduction particles encoding short hairpin RNA (shRNA) against CFTR were purchased from Jima Inc. (Shanghai, China). The sequences (5’ to 3’) of the two shRNAs were GAAAGTAGTATGGAAGATGTA and TTGGAAAGGAGACTAACAAGT, respectively. These two shRNA duplexes were from two different regions of human CFTR mRNA. Cells were plated in 24-well cell culture plates, incubated with 5 µL lentivirus (1 × 10⁹ TU·mL⁻¹, 1 × 10⁹ TU·mL⁻¹) for 24 or 48 h, and collected for analysis. Viral vectors containing noncoding shRNA were used as a control.

Western blotting

Cells were lysed in RIPA buffer with 1 : 100 protein inhibitor for 30 min on ice. The supernatants were collected as total protein after centrifugation at 15 000 g for 30 min. Equal amounts of protein were separated by sodium dodecyl sulfate polyacrylamide electrophoresis followed by western blotting. The protein bands were visualized by enhanced chemiluminescence (Millipore, Billerica, MA, USA) according to the manufacturer’s instructions, and data were quantified using densitometry analysis. Experiments were repeated three times, and the bands were scanned and quantified.

Immunohistochemistry and fluorescent immunocytochemistry

The sections were incubated with phosphate-buffered saline (PBS) for 5–10 min and retrieval buffer (citrate buffer, pH 6.0) for 30 min. After washing in PBS, the sections were incubated with primary antibodies overnight at 4 °C. The sections were then incubated with secondary antibodies for 60 min at room temperature. Finally, the sections were mounted with coverslips and visualized by microscopy.

RNA extraction and real-time quantitative polymerase chain reaction (RT/qPCR)

Total RNA was extracted using an RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) and was reverse-transcribed using a PrimeScript RT Master Mix kit (TaKaRa, Dalian, China) for standard real-time PCR analysis. RT/qPCR was performed using a TB Green Premix EX Taq II detection system in a Roche LightCycler 96 qPCR machine (Roche Diagnostics, Mannheim, Germany). Glyceraldehyde 3-phosphate dehydrogenase was used as a control. The gene-specific primers are summarized in Table S1.

Co-immunoprecipitation (Co-IP)

CFTR was overexpressed in 293T cells, and cells were cultured for 48 h. Cell lysates were collected in IP Lysis/Wash Buffer with a Pierce Crosslink Magnetic IP/Co-IP Kit (cat. no.: 88805; Thermo Scientific, Rockford, IL, USA). Cell lysates were then incubated with Protein A/G Magnetic Beads bound to CFTR antibodies for 2 h at room temperature. The beads were washed with IP wash buffer and then eluted in elution buffer to collect the target protein. Co-IP was performed according to the instructions provided by the kit manufacturer.

Three-dimensional (3D) structure of the CFTR/Hsp90 complex

Three-dimensional structures of CFTR (5TF7) and Hsp90 (6GPR) were downloaded from RCSB PDB. The complex
was built using PYMOL, version 2.0. The model contained the amino acids residues predicted as possible interacting sites [24,25].

**Statistical analysis**

Data were expressed as means ± standard deviations. Differences in measured variables between two groups were analyzed using Student’s t-tests, and differences between more than two groups were analyzed by one-way analysis of variance. Results with P values of < 0.05 were considered statistically significant.

**Results**

**Knockdown of CFTR**

Initially, we assessed the effects of shRNA against CFTR by western blotting. Caco2 and HRT18 cells were transfected with lentivirus for 48 h. Western blot analysis of CFTR protein was then performed. The results showed that CFTR was significantly downregulated (Fig. 1A). Moreover, in Caco2 cells, CFTR was not expressed at the apical membrane after knockdown (Fig. 1B).

**Knockdown of CFTR induced mitochondrial dysfunction by regulating the phosphorylation of AKT and ERK1/2**

To determine whether CFTR knockdown affected mitochondrial function in Caco2 and HRT18 cells, we performed western blot analysis of Bcl-2 family members, including Bcl-2, Bad, and Bax. The results showed that Bax and Bad were upregulated, and Bcl-2 was downregulated in CFTR-knockdown cells (Fig. 2A). In addition, the mRNA levels of Bax and Bad were upregulated, whereas Bcl-2 mRNA was downregulated in CFTR-knockdown cells (Fig. 2B).

To further explore the molecular mechanisms involved in mitochondrial dysfunction induced by CFTR knockdown, we measured the phosphorylation of AKT and ERK1/2, which regulate Bcl-2 family proteins. Western blot analysis indicated that phospho-AKT and phospho-ERK1/2 levels were decreased in CFTR-knockdown cells (Fig. 2C). These findings suggested that knockdown of CFTR induced mitochondrial dysfunction in Caco2 and HRT18 cells by regulating the phosphorylation of AKT and ERK1/2.

**CFTR interacted with Hsp90**

AKT and ERK1/2 are regulated by Hsp90 [26]; indeed, inhibition of Hsp90 induces the degradation of phospho-AKT and phospho-ERK1/2 [27–29]. Therefore, we next investigated the protein levels of Hsp90 in CFTR-knockdown cells. The results showed that both Hsp90α and Hsp90β decreased significantly in CFTR-knockdown Caco2 and HRT18 cells (Fig. 3A). To further investigate the relationships between CFTR and Hsp90, we performed Co-IP in CFTR-overexpressing 293T cells. The results showed that Hsp90 could be pulled down by CFTR (Fig. 3B). Although the 3D

![Fig. 1. Knockdown of CFTR.](image-url)
Fig. 2. Knockdown of CFTR induced mitochondrial dysfunction and degradation of phospho-AKT and phospho-ERK1/2. Caco2 cells and HRT18 cells were transfected with lentivirus, cultured, and collected. (A) Equal amounts of whole cell lysates (25–50 μg) were subjected to western blotting. The expression of Bcl-2 family proteins was detected. Actin was used as a loading control. Quantification of western blot results is shown in the right panel. (B) mRNA levels of CFTR, Bcl-2, and Bad were detected by RT/qPCR in CFTR-knockdown Caco2 and HRT18 cells. (C) Western blot analysis of phospho-AKT and phospho-ERK1/2 in CFTR-knockdown Caco2 and HRT18 cells. Actin was used as a loading control. Quantification of western blotting results is shown in the right panel. All data were expressed as means ± standard deviations. Differences in measured variables between two groups were analyzed using Student’s t-tests. **P < 0.01 (n = 3).
structures of both CFTR and Hsp90 were solved, the structure of the complex between these two proteins has not been determined experimentally yet. Therefore, we then built a model of the protein–protein interaction with PyMOL to predict the complex (Fig. 3C). These results indicated that degradation of phospho-ERK1/2 and phospho-AKT in CFTR-knockdown cells might be associated with decreased Hsp90 expression.

**Phospho-ERK1/2 and phospho-AKT were regulated by Hsp90**

To demonstrate that degradation of phospho-ERK1/2 and phospho-AKT was regulated by Hsp90, Caco2 and HRT18 cells were treated with 0.25 μM SNX-2112, a selective Hsp90 inhibitor, for 48 h [30]. The results showed that Akt mRNA levels were downregulated (Fig. 4A), and the levels of AKT protein, phospho-AKT, and phospho-ERK1/2 were also decreased (Fig. 4B) in SNX-2112-treated cells. Taken together, these data suggest that CFTR knockdown may induce mitochondrial dysfunction via Hsp90-mediated degradation of phospho-ERK1/2 and phospho-AKT (Fig. 4C).

**Discussion**

CFTR acts as a chloride channel and can interact directly or indirectly with several proteins by forming
a complex to regulate cell signaling processes [31]. Knockdown of CFTR suppresses the proliferation of ovarian cancer in vitro and in vivo [32]. In contrast, CFTR has also been reported to function as a tumor suppressor [33], and downregulation or mutation of CFTR activates proliferation, invasion, migration, and the epithelial–mesenchymal transition in breast cancer and prostate cancer [34–36]. Hyperproliferation has been observed in CF airways [37], and downregulation of CFTR has been reported in cancer tissues [33]. In addition, mitochondrial abnormalities have been reported in CF cells or tissues [38]. Differential expression of genes or proteins and alterations in calcium homeostasis, membrane potential, reactive oxygen species, and complex I activity have all been reported in mitochondria in the context of CFTR knockdown [39]. These mitochondrial effects in turn induce changes in the ratio of reduced/oxidized glutathione and trigger proliferation or apoptotic events.

Moreover, these alterations may influence the phenotype or clinical manifestations of CF [19,21,38,40]. However, the molecular mechanisms underlying mitochondrial dysfunction remain elusive.

In this study, we showed, for the first time, that disruption of the CFTR/Hsp90 interaction induced mitochondrial dysfunction via degradation of phospho-AKT and phospho-ERK1/2 in Caco2 and HRT18 cells. In CFTR-knockdown cells, Bax and Bad were activated, whereas Bcl-2 was inhibited, indicating the involvement of mitochondrial dysfunction. The mitochondria play important roles in apoptosis and proliferation [40]. Thus, further studies are needed to evaluate the roles of CFTR in mitochondrial dysfunction and subsequent cell proliferation and apoptosis.

AKT and ERK1/2 are crucial proteins that regulate the Bcl-2 family [41]. AKT upregulates Bcl-2 expression through cAMP-response element-binding protein [42]. Bad is a distant member of the Bcl-2 family and

![Fig. 4. Suppression of ERK1/2 and AKT phosphorylation by Hsp90 inhibition.](image)
can be phosphorylated by AKT and ERK1/2 [43–45]. In this study, both phospho-ERK1/2 and phospho-AKT levels were significantly decreased in CFTR-knockdown cells, suggesting that mitochondrial dysfunction induced by CFTR dysfunction may be regulated by the AKT and ERK1/2 pathways. AKT and ERK1/2 are the target proteins of Hsp90 [46], and inhibition of Hsp90 induces degradation of these proteins [47]. In this study, we found that Hsp90 was downregulated in CFTR-knockdown cells. Hsp90 interacted with CFTR. Hsp90 inhibitors induce the degradation of AKT and ERK1/2. Additional studies are needed to clarify the mechanisms mediating the interactions between CFTR and Hsp90. The regulation mechanisms of CFTR and Hsp90 on mitochondria, especially how CFTR and Hsp90 work together to maintain the function of mitochondria, will be investigated in the future work.

Taken together, our findings revealed a previously unidentified role of CFTR defects in mitochondrial abnormalities via the Hsp90-mediated degradation of phosphorylated ERK1/2 and AKT. These results provided novel insights into the physiological functions of CFTR and CF-related diseases.

Acknowledgements
This work was supported by grants from the Science and Technology Foundation of Shenzhen (JCYJ20180301170047864) and the National Natural Science Foundation of China (No. 81802749). This work was also supported by the Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis.

Conflict of interest
The authors declare no conflict of interest.

Author contributions
KL conceived and designed the experiments. KL, YG, and YL performed the experiments and analyzed the data. KL, HJ, YW, PZ, ZZ, JW, MW, CZ, WW, ZC, and YD contributed reagents/materials/analysis tools. KL wrote the manuscript.

References
1 Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenki J, Lok S, Plavsic N, Chou JL et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066–1073.
2 Couzin-Frankel J (2009) Genetics. The promise of a cure: 20 years and counting. Science 324, 1504–1507.
3 Chan HC, Shi QX, Zhou CX, Wang XF, Xu WM, Chen WY, Chen AJ, Ni Y and Yuan YY (2006) Critical role of CFTR in uterine bicarbonate secretion and the fertilizing capacity of sperm. Mol Cell Endocrinol 250, 106–113.
4 Kogan I, Ramjeesingh M, Li C, Kidd JF, Wang Y, Leslie EM, Cole SP and Bear CE (2003) CFTR directly mediates nucleotide-regulated glutathione flux. EMBO J 22, 1981–1989.
5 Liu Z, Guo J, Wang Y, Weng Z, Huang B, Yu MK, Zhang X, Yuan P, Zhao H, Chan WY et al. (2017) CFTR-beta-catenin interaction regulates mouse embryonic stem cell differentiation and embryonic development. Cell Death Differ 24, 98–110.
6 Liu K, Zhang X, Zhang JT, Tsang LL, Jiang X and Chan HC (2016) Defective CFTR- beta-catenin interaction promotes NF-kappaB nuclear translocation and intestinal inflammation in cystic fibrosis. Oncotarget 7, 64030–64042.
7 Loo MA, Jensen TJ, Cui L, Hou Y, Chang XB and Riordan JR (1998) Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J 17, 6879–6887.
8 Homma K, Miller KK, Anderson CT, Sengupta S, Du GG, Aguinha S, Cheatham M, Dallos P and Zheng J (2010) Interaction between CFTR and prestin (SLC26A5). Biochim Biophys Acta 1798, 1029–1040.
9 Sheppard DN, Carson MR, Ostedgaard LS, Denning GM and Welsh MJ (1994) Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium. Am J Physiol 266, L405–L413.
10 Rowe SM and Verkman AS (2013) Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 3, a009761.
11 Zhang X, Hothi JS, Zhang YH, Srinivasan S, Stokes DC and Zhang W (2016) c.3623G > A mutation encodes a CFTR protein with impaired channel function. Respir Res 17, 8.
12 Spielberg DR and Clancy JP (2016) Cystic fibrosis and its management through established and emerging therapies. Annu Rev Genomics Hum Genet 17, 155–175.
13 Pearson H (2009) Human genetics: one gene, twenty years. Nature 460, 164–169.
14 Aitken ML (1995) Cystic fibrosis. Curr Opin Pulm Med 1, 425–434.
15 Maiuri L, Raia V, De Marco G, Coletta S, de Ritis G, Londei M and Auricchio S (1997) DNA fragmentation is a feature of cystic fibrosis epithelial cells: a disease with inappropriate apoptosis? FEBS Lett 408, 225–231.
CFTR regulates the function of mitochondria

K. Liu et al.

16. Kleme ML, Sane A, Garofalo C, Seidman E, Brochiero E, Berthiaume Y and Levy E (2018) CFTR deletion confers mitochondrial dysfunction and disrupts lipid homeostasis in intestinal epithelial cells. *Nutrients* 10, 836.

17. Gottlieb RA and Dosanjh A (1996) Mutant cystic fibrosis transmembrane conductance regulator inhibits acidification and apoptosis in C127 cells: possible relevance to cystic fibrosis. *Proc Natl Acad Sci USA* 93, 3587–3591.

18. Feigal RJ and Shapiro BL (1979) Mitochondrial calcium uptake and oxygen consumption in cystic fibrosis. *Nature* 278, 276–277.

19. Antigny F, Girardin N, Raveau D, Frieden M, Becq F, l’Hoste S, Chargui A, Belfodil R, Corcelle E, Duranton E, Berthiaume Y and Levy E (2018) CFTR deletion models. *PLoS Comput Biol* 14, e1006238.

20. Xiao JS, Yang R, Shi WT, Li GY, Chen HP, Zhang Y, Yang K, Liu CB, Chen YG and Wang YF (2011) Preclinical pharmacokinetic analysis of SNX-2112, a novel Hsp90 inhibitor, in rats. *Biomed Pharmacother* 65, 132–136.

21. Groth M, Boursier P, Lemarchand-Peffault E, Poujeol P, Breton S, Medina D, Poujeol C, Mograbi B, Tauc M and Djouadi F (2011) 2D-electrophoresis of mitochondrial proteins from cystic fibrosis patients. *Adv Exp Med Biol* 690, 379–381.

22. Kelly-Aubert M, Trudel S, Fritsch J, Nguyen-Khoa T, Baudeau-Legros M, Moriceau S, Jeanson L, Djouadi F, Matar C, Conti M et al. (2011) GSH monoethyl ester rescues mitochondrial defects in cystic fibrosis models. *Hum Mol Genet* 20, 2745–2759.

23. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C, Gavina M, Pulze L, Giardino I, Pettoello-Mantovani M et al. (2010) Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. *Nat Cell Biol* 12, 863–875.

24. Kozakov D, Hall DR, Xia B, Porter KA, Padhory D, Yueh C, Beglov D and Vajda S (2017) The ClusPro web server for protein-protein docking. *Nat Protoc* 12, 255–278.

25. Sikic M, Tomic S and Vlahovicek K (2009) Prediction of protein-protein interaction sites in sequences and 3D structures by random forests. *PLoS Comput Biol* 5, e1000278.

26. Liu KS, Liu H, Qi JH, Liu QY, Liu Z, Xia M, Xing GW, Wang SX and Wang YF (2012) SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. *Cancer Lett* 318, 180–188.

27. Wang X, Wang S, Liu Y, Ding W, Zheng K, Xiang Y, Liu K, Wang D, Zeng Y, Xia M et al. (2014) The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress. *Biochem Biophys Res Commun* 446, 160–166.

28. Wang R, Shao F, Liu Z, Zhang J, Wang S, Liu J, Liu H, Chen H, Liu K, Xia M et al. (2013) The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/ NF-kappaB and disruption of mitochondria-dependent pathways. *Chem Biol Interact* 205, 1–10.

29. Wang SX, Ju HQ, Liu KS, Zhang JX, Wang X, Xiang YF, Wang R, Liu JY, Liu QY, Xia M et al. (2011) SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells. *Biosci Biotechnol Biochem* 75, 1540–1545.

30. Zhai QQ, Gong GQ, Liu Z, Luo Y, Xia M, Xing GW, You XF and Wang YF (2011) Preclinical pharmacokinetic analysis of SNX-2112, a novel Hsp90 inhibitor, in rats. *Biomed Pharmacother* 65, 132–136.

31. Mehta A (2005) CFTR: more than just a chloride channel. *Pediatr Pulmonol* 39, 292–298.

32. Xu J, Yong M, Li J, Dong X, Yu T, Fu X and Hu L (2015) High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo. *Onco Rep* 33, 2227–2234.

33. Than BL, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luzak T et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. *Oncogene* 35, 4179–4187.

34. Ruan YC, Wang Y, Da Silva N, Kim B, Diao RY, Hill E, Brown D, Chan HC and Breton S (2014) CFTR interacts with ZO-1 to regulate tight junction assembly and epithelial differentiation through the ZONAB pathway. *J Cell Sci* 127, 4396–4408.

35. Zhang JT, Jiang XH, Xie C, Cheng H, Da Dong J, Wang Y, Fok KL, Zhang XH, Sun TT, Tsang LL et al. (2013) Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer. *Biochim Biophys Acta* 1833, 2961–2969.

36. Xie C, Jiang XH, Zhang JT, Sun TT, Dong JD, Sanders AJ, Diao RY, Wang Y, Fok KL, Tsang LL et al. (2013) CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. *Oncogene* 32, 2282–2291, 2291 e1–7.

37. Leigh MW, Kylander JE, Yankaskas JR and Boucher RC (1995) Cell proliferation in bronchial epithelium and submucosal glands of cystic fibrosis patients. *Am J Respir Cell Mol Biol* 12, 605–612.

38. Valdivieso AG and Santa-Coloma TA (2013) CFTR activity and mitochondrial function. *Redox Biol* 1, 190–202.

39. Valdivieso AG, Clauzure M, Marín MC, Taminelli GL, Massip Copiz MM, Sánchez F, Schulman G, Teiber...
ML and Santa-Coloma TA (2012) The mitochondrial complex I activity is reduced in cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function. *PLoS ONE* 7, e48059.

40 Merkwirth C, Dargazanli S, Tatsuta T, Geimer S, Löwer B, Wunderlich FT, von Kleist-Retzow JC, Waisman A, Westermann B and Langer T (2008) Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. *Genes Dev* 22, 476–488.

41 Asnaghi L, Calastretti A, Bevilacqua A, D’Agnano I, Gatti G, Canti G, Delia D, Capaccioli S and Nicolin A (2004) Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. *Oncogene* 23, 5781–5791.

42 Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE and Reusch JE (2000) Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. *J Biol Chem* 275, 10761–10766.

43 Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T and Murata Y (2000) Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. *Cancer Res* 60, 5988–5994.

44 Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y et al. (2002) Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. *J Biol Chem* 277, 33490–33500.

45 Grund K, Ahmadi R, Jung F, Funke V, Gdynia G, Benner A, Sykora J, Walczak H, Joos S, Felsberg J et al. (2008) Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. *Cancer Biol Ther* 7, 1982–1990.

46 Liu KS, Zhang Y, Ding WC, Wang SX, Xiang YF, Yang P, Chen ZP, Zheng K, Liu Z, Xia M et al. (2012) The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human esophageal squamous carcinoma cells. *Int J Oncol* 41, 5988–5994.

47 Ju HQ, Wang SX, Xiang YF, Liu Z, Liu JY, Chen ZP, Zeng FL, Xia M, Liu ZH, Xing GW et al. (2011) BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway. *Eur J Pharmacol* 666, 26–34.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. The oligonucleotide primer sequences for RT-qPCR.